A randomized comparison between early and late vaccination with tetanus toxoid vaccine after allogeneic BMT

被引:44
作者
Parkkali, T [1 ]
Olander, RM [1 ]
Ruutu, T [1 ]
Vuontela, K [1 ]
Volin, L [1 ]
Eskola, J [1 ]
Ruutu, P [1 ]
机构
[1] NATL PUBL HLTH INST,HELSINKI,FINLAND
关键词
tetanus vaccination; vaccination response; BMT recipients;
D O I
10.1038/sj.bmt.1700768
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Forty-five adult HLA-matched sibling BMT recipients were randomized to receive tetanus toroid (TT) vaccine at 6, 8 and 14 months (early group, n = 23) or at 18, 20 and 26 months after BMT (late group, n = 22). At 6 months after BMT, prior to the first vaccination, 90% of the early group patients had a protective tetanus antibody concentration of greater than or equal to 0.1 HU/ml (passive haemagglutination test) but only 70% of the late group patients did so at 18 months after BMT. The antibody responses 1 month after each of the three TT vaccine doses were similar in the two vaccination groups, except that after the first dose, four-fold responses occurred more frequently in the late group. All vaccinated patients achieved the protective antibody concentration of greater than or equal to 0.1 HU/ml. In the late group the recipient antibody responses after the first and second vaccine doses correlated with the donor anti-TT level. A tetanus vaccination schedule consisting of three vaccine doses is equally immunogenic when started at 6 or 18 months after BMT. Donor immunity against tetanus may influence recipient responses to TT vaccination.
引用
收藏
页码:933 / 938
页数:6
相关论文
共 24 条
[1]  
ALANKO S, UNPUB RESPONSES TETA
[2]   THE USE OF AN IMMUNOENZYMATIC ASSAY FOR THE ESTIMATION OF TETANUS ANTITOXIN IN HUMAN-SERA - A COMPARISON WITH SERONEUTRALIZATION AND INDIRECT HEMAGGLUTINATION [J].
GENTILI, G ;
PINI, C ;
COLLOTTI, C .
JOURNAL OF BIOLOGICAL STANDARDIZATION, 1985, 13 (01) :53-59
[3]   POLYSACCHARIDE CONJUGATE VACCINE RESPONSES IN BONE-MARROW TRANSPLANT PATIENTS [J].
GUINAN, EC ;
MOLRINE, DC ;
ANTIN, JH ;
LEE, MC ;
WEINSTEIN, HJ ;
SALLAN, SE ;
PARSONS, SK ;
WHEELER, C ;
GROSS, W ;
MCGARIGLE, C ;
BLANDING, P ;
SCHIFFMAN, G ;
FINBERG, RW ;
SIBER, GR ;
BOLON, D ;
WANG, M ;
CARIATI, S ;
AMBROSINO, DM .
TRANSPLANTATION, 1994, 57 (05) :677-684
[4]  
LIVOLTI S, 1994, BONE MARROW TRANSPL, V14, P225
[5]   EFFICACY AND SAFETY OF VACCINATION OF MARROW TRANSPLANT RECIPIENTS WITH A LIVE ATTENUATED MEASLES, MUMPS, AND RUBELLA VACCINE [J].
LJUNGMAN, P ;
FRIDELL, E ;
LONNQVIST, B ;
BOLME, P ;
BOTTIGER, M ;
GAHRTON, G ;
LINDE, A ;
RINGDEN, O ;
WAHREN, B .
JOURNAL OF INFECTIOUS DISEASES, 1989, 159 (04) :610-615
[6]  
LJUNGMAN P, 1995, BONE MARROW TRANSPL, V15, P455
[7]  
LJUNGMAN P, 1991, BONE MARROW TRANSPL, V7, P89
[8]   RESPONSE TO TETANUS TOXOID IMMUNIZATION AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].
LJUNGMAN, P ;
WIKLUNDHAMMARSTEN, M ;
DURAJ, V ;
HAMMARSTROM, L ;
LONNQVIST, B ;
PAULIN, T ;
RINGDEN, O ;
PEPE, MS ;
GAHRTON, G .
JOURNAL OF INFECTIOUS DISEASES, 1990, 162 (02) :496-500
[9]  
LUM LG, 1986, BLOOD, V67, P582
[10]  
LUM LG, 1988, BONE MARROW TRANSPL, V3, P399